We're here to help during Covid-19. Find out more here.
The purpose of this study is to determine whether treatment with alpelisib in combination with abraxane is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss without PIK3CA mutation (Study Parts B1 and B2)
Who is it for?
You may be eligible for this study if you meet the below criteria:
Alpelisib + abraxane: Drug: Patients will be administered 300mg alpelisib orally once per day and 100 mg/m² abraxane as IV infusion on Days 1, 8 and 15 of a 28-day cycle.
Placebo + abraxane: Drug: Patients will be administered 300mg placebo orally once per day and 100 mg/m² abraxane as IV infusion on Days 1, 8 and 15 of a 28-day cycle.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at firstname.lastname@example.org
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to email@example.com
Subscribe for updates & stay in the loop with new studies.